BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Tops Revenue Estimates
BCRXBioCryst Pharmaceuticals(BCRX) Zacks Investment Research·2024-05-06 21:11

BioCryst Pharmaceuticals (BCRX) came out with a quarterly loss of 0.17pershareversustheZacksConsensusEstimateofalossof0.17 per share versus the Zacks Consensus Estimate of a loss of 0.23. This compares to loss of 0.28pershareayearago.Thesefiguresareadjustedfornon−recurringitems.Thisquarterlyreportrepresentsanearningssurpriseof26.090.28 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 26.09%. A quarter ago, it was expected that this drugmaker would post a loss of 0.24 per share when it actually produced a loss of $0.28, delivering a surprise of -16.67%. Over the last four quarters, the compan ...